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Abstract
Background: Since its founding in 2002, the Global Fund to Fight AIDS, Tuberculosis, and Malaria (Global Fund) has
become the dominant multilateral health financier in low- and middle-income countries. The health impact of the
Global Fund remains unknown because existing evaluations measure intermediate outcomes or do not account for
preexisting and counterfactual trends.
Methods: We conducted an econometric analysis of data from all countries eligible to receive Global Fund grants
from 1995 to 2010, prior to and during the Global Fund’s activities. We analyzed three outcomes: all-cause adult
(15–59 years), all-cause under-five, and malaria-specific under-five mortality. Our main exposure was a continuous
longitudinal measure of Global Fund disbursements per capita. We used panel fixed effect regressions, and analyzed
mortality trends controlling for health spending, health worker density (a measure of health system capacity), gross
domestic product, urbanization, and country fixed-effects.
Results and discussion: We find that following Global Fund disbursements, adult mortality rate declined by 1.4 % per
year faster with every $10 per capita increase in disbursements (p = 0.005). Similarly, malaria-specific under-five mortality
declined by 6.9 % per year faster (p = 0.033) with every $10 high per capita Global Fund disbursements. However, we
find no association between Global Fund support and all-cause under-five mortality. These findings were consistent
after subanalyses by baseline HIV prevalence, adjusting for effects of concurrent health aid from other donors, and
varying time lags between funding and mortality changes.
Conclusions: Grants from the Global Fund are closely related to accelerated reductions in all-cause adult mortality and
malaria-specific under-five mortality. However, up to 2010 the Global Fund has not measurably contributed to reducing
all-cause under-five mortality.
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Background
Development assistance to the health sector of developing
countries has increased by over 3-fold between 1990 and
2012 [1, 2]. A central institution involved in this growth
has been the Global Fund to Fight AIDS, Tuberculosis,
and Malaria (Global Fund). From its founding in 2002
through the end of 2012, the Global Fund disbursed nearly
$19 billion (current USD) in development assistance to
disease control programs in nearly 140 countries [3]. Dur-
ing this period, the Global Fund has become the dominant
multilateral funder of health programs in low- and middle-
income countries.
To date, the Global Fund has focused on financing
HIV/AIDS, tuberculosis, and malaria programs. Among
these, HIV/AIDS programs received the most funding,
and tuberculosis the least [3]. Through 2012, the Global
Fund determined funding eligibility based on country in-
come, past and ongoing Global Fund grant performance,
and, for upper-middle income countries, disease burden
and development assistance from other sources [4].
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The Global Fund actively supports program evaluations,
although these have mostly focused on process measures
rather than health outcomes [5, 6]. The Global Fund’s an-
nual Results Report calculate number of lives saved using
models that rely on the efficacy of financed goods such as
antiretroviral therapy (ART) to translate service delivery
outputs into mortality benefits [7]. However, this approach
does not account for differences between theoretical effi-
cacy and real-world effectiveness, or for mortality changes
that are unrelated to the Global Fund’s support [8].
We provide a quantitative assessment of the relationship
between Global Fund disbursements and subsequent
changes in key health outcomes: all-cause adult mortal-
ity, all-cause under-five mortality, and malaria-specific
under-five mortality. Quantifying the mortality changes
related to Global Fund support is important for several
areas of global health policy. First, understanding and
optimizing the Global Fund’s health outcomes has dir-
ect implications for the health of millions: the oppor-
tunity cost of ineffectiveness is high. Second, estimating
the Global Fund’s effectiveness makes an important con-
tribution to the growing science of health aid effective-
ness, and is an important input for measuring the value
provided by the organization [9]. Third, additional data
and analyses are needed to inform the broad policy ques-
tions over the extent to which health aid improves health
outcomes. Finally, the Global Fund regularly implements
changes to its resource allocation decisions to maximize
impact, and understanding the Global Fund’s overall rela-
tionship with mortality patterns, especially child mortality,
where the Global Fund’s impact is less certain, could
provide important information for future strategic plan-
ning [10–12].
Methods
Approach
Our overall approach examines the relationship between
Global Fund disbursement and longitudinal mortality
trends among all countries ever eligible to receive Global
Fund grants prior to and during the Global Fund’s period
of activity, from 1995 to 2010. The baseline period be-
tween 1995 and 2002 (prior to the Global Fund) allows us
to analyze the role of pre-existing and baseline trends.
Global fund support
We analyzed data from all countries that ever received
Global Fund disbursements, and countries that were eli-
gible to apply for grants but did not receive any disburse-
ments, between 2002 and 2010. Eligible non-recipients
included several countries who had applied unsuccessfully,
or whose eligibility had changed over time. In compiling
support, we examined grant disbursements to individual
countries as well as through multi-country grants. We allo-
cated multi-country grants evenly among recipients [8, 13].
We operationalized Global Fund support (the princi-
pal exposure) as a continuous variable of Global Fund
support per capita. Global Fund support was calculated
as the total disbursements between 2002 and 2010, includ-
ing multi-country grants. When examining all-cause adult
and under-five mortality, we used Global Fund disburse-
ments across all disease programs (HIV, TB, and malaria);
however, we used only malaria grants when examining
malaria-specific mortality. We denominated Global Fund
disbursements by the population size as a measure of ex-
posure because our intent was to look at the relationship of
Global Fund disbursements with population-level changes
in health outcomes. In addition, our assumptions about
possible mechanisms of effectiveness flowed from dis-
bursements to health through both treatment and pre-
vention efforts, thereby rendering the entire population
as potential beneficiaries.
To allow for the time elapsed from donor disburse-
ments, in-country recipient expenditures on disease con-
trol programs, improved delivery of health services to the
intended population, and mortality effects, our models
lagged the earliest possible effect between disbursements
and mortality by one year; we also capped the duration
through which mortality effects could be detected at three
years after the earliest year of putative effect [14, 15]. For
example, our models measured any mortality effects re-
lated to disbursements in 2002 over the period between
2003 and 2005.
Mortality outcomes
We focused on three mortality indicators: all-cause adult
mortality, all-cause under-five mortality, and malaria-
specific under-five mortality [16–18]. We included
malaria-specific under-five mortality because it is a key
impact indicator for the Global Fund, the disbursements
devoted to malaria have increased substantially during
the study period, and malaria makes up a sizable propor-
tion of all-cause under-five deaths in many of the coun-
tries that receive Global Fund malaria grants [8, 19]. We
used annual country-level mortality estimates produced
by the Institute for Health Metrics and Evaluation
(IHME) [16–18, 20]. Adult mortality was measured as
the probability that a 15-years-old person would die by
age 59 (45q15); under-five mortality as the probability of
dying before age 5 per 1000 live births (5q0); and malaria-
specific under-five mortality as the probability of death
from malaria per 1000 child-years at risk. We log-
transformed all mortality rates to reduce skewness and be-
cause it facilitates an intuitive interpretation of changes in
mortality as percentages. IHME estimates were used
because they represent the most complete source of
longitudinal mortality data in all countries of interest.
The information used by IHME to generate its mortal-
ity estimates varies by country, but it does not include
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Global Fund (or any health aid) information in generat-
ing its estimates.
Covariates
We chose and specified four time-varying covariates to
examine and adjust for important potential confounders
of the relationship between Global Fund disbursements
and mortality changes. First, we explicitly considered the
possibility that the Global Fund targeted countries with
relatively more capable health systems, so that improv-
ing outcomes may appear to be related to Global Fund
support whereas in reality they reflect these countries’
stronger underlying health system. We adjusted for
health workforce density according to the Global Health
Workforce Statistics database, defined as the number of
physicians and nurses per 100,000 population [21, 22].
This indicator is closely related to measures of health
system performance such as vaccination coverage and
possibly reflects the capacity of recipient countries to ef-
fectively implement public health programs. Missing
country-year observations were replaced with country-
specific mean, and a log-transformed density was used
in the final analysis. We checked the sensitivity of the
findings to the missing data by repeating the main ana-
lyses after dropping all missing data. This analysis did
not substantively change the findings, and is not shown.
We used two covariates to represent the role of social
and economic development as correlates of mortality
changes: real gross domestic product per capita (GDPpc)
measured in constant 2005 international dollars, and the
percentage of population living in urban areas from the
World Development Indicators [23]. Finally, we included
health spending per capita [24]. Health spending may it-
self drive mortality reductions, and in addition may influ-
ence funding preferences: the Global Fund views health
funding from recipient public sources (“Domestic coun-
terpart Funding”) favorably, and health expenditures are
an indicator of preferential Global Fund support [25]. In
addition to the time-varying covariates, all analyses in-
cluded country fixed-effects to control for time-invariant
differences among countries, including fixed baseline or
pre-existing differences. For example, if the Global Fund
made early commitments based on recipients’ baseline
health system capacity in 2002, that time-invariant differ-
ence is controlled for with country fixed effects.
Statistical approach and sensitivity analyses
We used panel fixed effect regressions that examine within-
country changes in mortality in relation to timing and levels
of Global Fund disbursements. In the primary analysis, dis-
bursements per-capita were interacted with a time trend
variable. The coefficient thus represents the magnitude of
the change from pre-existing mortality trends with each in-
crease of $1 per capita in Global Fund disbursements. All
models included country fixed effects and the time-varying
covariates. In addition, the health workforce density covari-
ate was included as an interaction with the main effect pa-
rameters to examine for effect modification due to the
Global Fund’s possible funding selection based on health
system capacity. The primary regression models, then, can
be represented as follows:
Mortalityit ¼ γi þ β1  trendt
þβ2  trendt  FundPerCapit
þβ3  trendt  FundPerCapit
HealthWorkforceDensityit þ Zitα þ X itδ þ εit
Where Mortalityit is the log-transformed mortality rates
for country i in year t, trendt is a time trend taking on the
value t in the tth year, FundPerCapit are the per-capita dis-
bursements from the Global Fund, HWDit is the health
workforce density, Xit is a vector of country-year covari-
ates including real gross domestic product per capita,
health expenditures per capita and the percentage of
population living in the urban area., and γi denotes the
fixed effect coefficient of country i. The terms that expli-
citly relate to the mortality trend are shown in the equa-
tion; the variables that are not interacted with trendt are
consolidated into the matrix term Zitα. Robust standard
errors clustered by country were calculated in all ana-
lyses. Additional regression details are in Additional file
1: S1 (Statistical Models).
Several additional analyses supported the main findings.
First, we repeated the primary models in two sub-
analyses: one in country subsets divided into tertiles by
HIV prevalence around the start of the Global Fund, and
a second restricted to the subset of sub-Saharan African
countries (Additional file 1: S2), because of the Global
Fund’s heavy investments and the unique disease burden
of HIV, tuberculosis, and malaria in this region. Second,
we examined the possibility that concurrent funding from
the US President’s Emergency Plan for AIDS Relief (PEP-
FAR) confounded the observed Global Fund effects. A
variable identifying PEPFAR support was introduced alone
and in interaction with the Global Fund disbursement var-
iables to test for effect modifications (Additional file 1:
S3). Third, we explored additional models, including con-
trolling for health aid disbursements from organizations
other than the Global Fund, added unadjusted models
without covariates that may be influenced by Global Fund
support, trimmed the most uncertain estimates, replaced
time trends with year fixed effects, and added country-
specific time trends (Additional file 1: S4). Fourth, we var-
ied the lag length between disbursements and possible start
of mortality effects – 1 year in the default analysis – to 2–4
years (Additional file 1: S5). Fifth, in assessing malaria mor-
tality, we denominated disbursements per person at risk of
malaria in each country (Additional file 1: S6), as alternative
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to per capita in the default analysis. As a final test of
uncertainty, we used the mortality bounds provided
by IHME to sample from the distribution of plausible
values and repeated the analyses 1000 times to gener-
ate a distribution of estimated coefficients (Additional
file 1: S7).
All analyses used Stata 13.1 (Statacorp Inc). All data
sources are indicated in the paper. In addition, the analytic
code is provided along with the article as Supporting In-
formation files. Additional file 2 Additional file 3 and
Additional file 4.
Ethics
This analysis has been assessed as exempt from eth-
ics review by Stanford’s Human Subjects Research &
IRB Office.
Results
Baseline and descriptive findings
We analyzed data from all countries that were eligible
for support from the Global Fund up to 2010 (Fig. 1).
The average total disbursements per-capita between
2002 and 2010 for all study countries was $1.08 (in con-
stant 2005 US dollars); in a wide distribution ranging
from $0.1 per capita among the lowest tertile of recipi-
ents to $2.68 among the highest tertile of recipients
(Table 1). The Global Fund’s per-capita disbursements
increased three-fold during the period from 2007 to
2010, compared with its first five years of operation,
from $0.57 to $1.73 Malaria funding also showed high
variability when measured in disbursements per capita.
Of the 51 countries in the highest tertile of per capita
malaria disbursements, 28 were in sub-Saharan Africa.
In 2002, average all-cause mortality among children and
adults were 3-fold and 2-fold higher, respectively, in the
highest compared with the lowest tertile countries.
Global fund and all-cause adult mortality
Higher Global Fund disbursements per capita were
followed by greater declines in adult mortality. Figure 2a
shows the temporal pattern of adult mortality by tertile
of Global Fund support. The Figure suggests that, prior
to the Global Fund, adult mortality was rising among
the countries that ended up as the highest recipients,
that this rise slowed just prior to start of Global Fund
disbursements, and that it changed into a decline following
the initiation of support. A similar pattern, though less dra-
matic, is seen among countries in the middle tertile: rising
adult mortality rates followed by a reversal of mortality
rates following start of Global Fund disbursements. In con-
trast, countries at the lowest tertile of support experienced
Fig. 1 Geographical distribution of Global Fund support. Countries are shaded according to the tertile of per capita total Global Fund disbursements
between 2002 and 2010, from lowest (lightest) to highest (darkest)
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declining mortality before Global Fund disbursements, and
these declines continued along a similar trend after start of
Global Fund support.
The regression results shown in Table 2 and Additional
file 1: S2-S5 provide additional support for these relation-
ships. We estimate that a $10 increase in Global Fund dis-
bursements per capita was followed by a 1.4 % greater
annual decline in all-cause adult mortality (p = 0.005).
This effect was not significantly modified by an interaction
with health workforce density, suggesting similar Global
Fund effects on adult mortality irrespective of baseline or
evolving national health system capacity. For example, in
a country receiving Global Fund disbursements of $10 per
capita per year, and where all-cause adult mortality de-
clined from 400 to 345 per 1000 adults over a 5-year
period (a 3 % annual decline), our analysis suggests that,
absent the Global Fund, adult mortality would have
dropped only from 400 to 369 per 1000 adults (a 1.6 % an-
nual decline). In a country like South Africa with approxi-
mately 28 million adults between 15 and 60 years old,
these comparative mortality trends imply approximately
190,588 fewer adult deaths associated with 5 years of Glo-
bal Fund support.
All-cause under-five mortality
Unlike for all-cause adult mortality, our analysis fails to in-
dicate that any reductions in all-cause under-five mortality
during the past decade could be attributed to Global Fund
support. While the decline in under-five mortality was
fastest in the countries receiving most assistance, there is
no evidence of a subsequent acceleration in this trend
after start of Global Fund disbursements (Fig. 2b). The
regression analyses reflect these observations: changes
in under-five mortality that may be attributable to the
Global Fund are negligible and not statistically signifi-
cant (Table 2). Similar to our findings with adult mor-
tality, health workforce density did not significantly
interact with the effect of Global Fund support. These
findings make the possibility of spurious associations
Table 1 Descriptive characteristics of countries, at different levels Global Fund per capita disbursements
All Eligible counties Highest tertile Middle tertile Lowest tertile % imputed data
Number of countries 152 51 51 50 –
Average real GDP per capita in 2002–2010
(in constant 2005 international dollar)
6426 3720 5174 10,406 0 %
Average public health expenditure per capita
(net of GF) in 2002–2010 (in constant 2005 US dollars)
216 118 145 349 0.23 %
Average percentage of population living in urban area
in 2002-2010
48 37 49 58 0 %
Total Global Fund disbursements per capita
(in constant 2005 US dollars)
1.08 2.68 0.71 0.10 0 %
2002-2006 0.57 1.40 0.38 0.05
2007-2010 1.73 4.30 1.12 0.16
All-cause adult mortality rate2
1995 246 316 254 171 0 %
2002 247 331 259 156 0 %
2007 241 326 253 150 0 %
2008 238 323 250 147 0 %
2009 236 321 248 144 0 %
2010 235 318 245 144 0 %
All-cause under-five mortality rate3
1995 77 104 86 41 0 %
2002 62 86 70 33 0 %
2007 54 74 61 27 0 %
2008 52 73 60 26 0 %
2009 51 72 58 25 0 %
2010 50 71 57 25 0 %
Notes:
1Funding groupings used Global Fund disbursements for all sectors (HIV/AIDS, TB, malaria and Health Systems Strengthening)
2Adult mortality is expressed as the probability that a 15-year-old person would die by age 59 per 1000 adults (45q15)
3Child mortality is expressed as the number of deaths before age 5 per 1000 live births (5q0)
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due to funding prioritization according to health system
or program implementation capacity less likely.
Malaria-specific under-five mortality
We find evidence accelerating malaria-specific under-five
mortality declines following Global Fund malaria disburse-
ments. Figure 2c shows that a downward bend in malaria
mortality trends among the top two tertiles of recipient
countries started 1–2 years following initial Global Fund
malaria disbursements. The regression analysis supports
this impression: each $10 increase in Global Fund dis-
bursements per capita for malaria was associated with a
6.9 % subsequent greater annual decline in malaria-specific
under-five mortality. These findings were robust when
Global Fund support was expressed per person living in
areas at risk of malaria (Additional file 1: S5), instead of
per capita of total national population in the default ana-
lysis. When restricting the analysis to sub-Saharan Africa,
the magnitude of the malaria-specific mortality declines
following Global Fund disbursements is lower (3.6 %) and
not statistically significant (p = 0.247).
Sensitivity analyses
The direction and size of observed associations were con-
sistent across all-cause adult and all-cause child mortality
specifications when repeating the analysis in the subset of
Sub-Saharan countries only. When considering the find-
ings in relation to countries’ relative HIV burden, the de-
clines in adult mortality were greatest in those countries
with the highest baseline HIV prevalence, suggesting
that reductions in HIV-related mortality have likely
been instrumental in causing mortality declines (Add-
itional file 1: S2).
We also examined the sensitivity of findings to possible
synergy and/or confounding of Global Fund funding with
PEPFAR funding, which clustered in an overlapping set of
highest-recipient countries (Additional file 1: S3). We find
that PEPFAR did not meaningfully modify the effect of the
Global Fund for either adults or children. While past stud-
ies suggest that PEPFAR played a role in declining adult
mortality, our findings suggest that this effect is inde-
pendent from that of Global Fund support [26]. A final
robustness check varied the lag duration between disburse-
ment and start of possible mortality effects from 1 year (in
Fig. 2 Mortality trends relative to year of first Global Fund disbursements among eligible countries, divided into tertiles of per capita disbursements:
a all-cause adult mortality, b all-cause under-five mortality, and c malaria-specific under-five mortality. The mortality rate of each country is presented as
the difference between the country’s year-specific mortality and its mean mortality between 1995 and 2010 (de-meaned). Each funding group’s mortality
rate is the average of the de-meaned values for all countries within the group, thus removing from the graphs the large mortality level differences between
groups that persisted throughout the time period evaluated (see Table 1), and approximating the fixed-effects regression. For each country,
Year 0 represents the first year of support from the Global Fund
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the default analysis) up to 4 years (Additional file 1: S5).
Extending the minimum lag between disbursements
and mortality changes decreased the magnitude of the
attributable reductions in malaria-specific under-five
mortality.
Discussion
Our analysis on the relationship between grants from
the Global Fund and mortality changes in recipient
countries suggests that Global Fund disbursements
were followed by accelerated reductions in all-cause
adult mortality, and these mortality reductions in-
creased with increasing Global Fund support. This rela-
tionship was most strongly observed in countries with a
high HIV prevalence, consistent with the notion that
large global health initiatives have played a role in the
changing epidemiology of HIV-related and, thereby, all-
cause adult mortality. We also find a close relationship
between malaria funding and accelerating declines in
malaria-specific under-five mortality. However, we fail
to find evidence that the Global Fund was associated
with accelerated reductions in all-cause under-five
mortality.
The lack of Global Fund effect on all-cause under-five
mortality (despite large apparent effects on malaria-specific
under-five mortality) requires further discussion. We ob-
serve an absence of change in child mortality trends fol-
lowing Global Fund grants. We speculate that Global Fund
grants may have failed to contribute to accelerating child
mortality declines because in many recipient countries the
main causes of under-five mortality are diarrhea, pneumo-
nia, and malnutrition (and not malaria, tuberculosis, or
HIV), which Global Fund-supported disease programs do
not target [27, 28]. The absence of observed changes in all-
cause under-5 mortality and declines in malaria-specific
under-5 mortality may result from the use of different ex-
posures as well as from the fact that malaria makes up a
small portion of all-cause under-5 mortality in many
countries. We also observe that the magnitude of the
declines in malaria-specific under-5 mortality is smaller
in sub-Saharan Africa compared with the overall sam-
ple (Additional file 1: S2). While we cannot explain this
observation, we speculate that this could possibly be
explained by the relatively high burden of falciparum
malaria, relatively high transmission risk, unique vector
control challenges, or less effective use of Global Fund
resources in sub-Saharan Africa.
The lack of a relationship between disbursements and
all-cause under-five mortality could inform ongoing Glo-
bal Fund strategic decisions to expand its support beyond
the three diseases, maximizing and leveraging synergies
between supported disease control programs and neo-
natal, infant and child health strategies and systems more
broadly [29]. These considerations are articulated in Glo-
bal Fund documents, but under-five mortality reduction
has not been a distinct strategic priority to date [12]. Ex-
ternal Global Fund evaluations proposed approaches for
exploiting synergies between malaria and integrated
Table 2 Relationship of Global Fund support to adult and under-five mortality changes
All-cause adult mortality All-cause under-five mortality Malaria-specific child mortality
(p-value)5 (p-value)5 (p-value)5,6
Global Fund $ per capita1 −0.0014 (0.005) −0.0005 (0.33) −0.0069 (0.033)
Global Fund $ per capita × HWD2 0.0013 (0.72) −0.0005 (0.25) 0.0016 (0.40)
Health workforce density (HWD) 2 −0.0021 (0.090) −0.0022 (0.11) −0.0094 (0.15)
GDPpc (logged, in 2005 USD, PPP adjusted)3 −0.0587 (0.16) −0.1484 (0.067) −0.6625 (0.032)
% of urban population 0.0010 (0.77) −0.0050 (0.23) 0.0178 (0.54)
Health expenditure per capita (logged, in 2005 USD)4 −0.0018 (0.92) −0.0078 (0.60) −0.0503 (0.55)
Number of countries 147 147 55
Number of country-year observations 2322 2322 856
Notes:
1Global Fund disbursements per capita in constant 2005 USD. A significant negative coefficient indicates effectiveness of Global Fund in bending down the
mortality trend. The coefficient indicates that the mortality rate declined by coefficient × 100 percent faster per year for every $1 increase in per
capita disbursements
2HWD is health workforce density, defined as the number of doctors and nurses per 100,000 population, an indicator of health system capacity. All HWD
estimates were log-transformed. The interactions between HWD and the Global Fund variables indicate whether, at any level of Global Fund exposure, the
observed outcomes changed based on HWD. The coefficient of the interactive term measures how the health workforce density in a country modifies the
effectiveness of Global Fund in changing the mortality trend. There is no evidence that the effect of Global Fund on mortality was meaningfully different
based on health system capacity as measured through HWD
3Gross domestic product per capita, log-transformed, in 2005 USD, adjusted for purchasing power parity
4Total health expenditures minus Global Fund disbursements from all sources per capita in 2005 USD
5Mortality rates are log-transformed, so that the coefficient values can be interpreted as the additional annual proportional change in mortality with each additional year
of support from the Global Fund (see numerical examples in Results text)
6The malaria-specific models analyze countries with high, severe or extreme malaria burden. According to the Global Fund’s eligibility criteria, these are the
countries with burden defined as high, severe, or extreme; countries with low or moderate burden were excluded, resulting in the analysis of 55 countries.
Only malaria grants were used to examine malaria-specific mortality
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management of childhood illnesses as potential ap-
proaches to enhance the Global Fund’s health impact, but
such cross-program approaches have not been widely
adopted to date. Our results furthermore suggest a role
for measuring broad health indicators such as all-cause
mortality to assess the contributions of large global health
initiatives to population health.
We find a significant and robust effect on all-cause
adult mortality, across all countries eligible for Global
Fund support, within Sub-Saharan Africa as well as in
the country subgroup with the highest HIV prevalence.
In addition, we find that concurrent program funding
from PEPFAR does not diminish the relationships be-
tween Global Fund support and all-cause adult mortal-
ity. Our analysis thus does not find support for a
hypothesized antagonistic effect of large global health
initiatives, such as those postulated to result from orga-
nizations that duplicate efforts while incurring adminis-
trative overheads without adding value [30].
Limitations
This analysis uses aggregated, smoothed mortality esti-
mates that were generated using sophisticated demo-
graphic and epidemiological models [31]. While some
studies question the data we use for all-cause under-five
mortality and malaria mortality, especially among adults
outside Africa, there is broader agreement on malaria-
specific under-five mortality levels and trends, and the
consensus around all-cause under-five mortality is grow-
ing for many countries (with the possible exception of
some countries with high HIV burden) [32, 33]. In
addition, the data sources underlying these mortality esti-
mates (such as the Demographic and Health Surveys) are
of high quality [16]. Our primary analyses use the point
estimates generated by IHME, though the uncertainty
from the underlying data-generating process may be sub-
stantial. We make an effort to address this uncertainty by
trimming the least reliable observations, thereby empha-
sizing observations with less uncertainty (Additional file 1:
S4). In addition, the data we use for adult mortality is ar-
rived at using lagged, smoothed GDPpc estimates (among
other predictor variables). The use of GDPpc as an input
to our models leave open questions about our ability to
adequately control for overall level of economic develop-
ment. We considered other data sources for this analysis,
including the United Nations Inter-agency Group for
Child Mortality Estimation for under-5 mortality and the
Demographic and Health Surveys (DHS). The DHS data is
available for only approximately 90 countries, and less
during the study period. We also preferred IHME data be-
cause it uses a consistent methodology and underlying
data sources for estimating adult, child, and malaria-
specific mortality, thus limiting the measurement
challenges that might arise from using different estimation
methods.
Our fixed effects approach relaxes some of the limita-
tions to causal inferences from ecological associations,
yet unmeasured drivers of mortality changes that may
cluster with the Global Fund in time and in geograph-
ical distribution remain a concern. Notably, it is pos-
sible that receipt of Global Fund support may correlate
with a country’s intrinsic public health capacity [10].
Our inclusion of health system capacity measures
(proxied by health workforce density), and their pos-
sible interaction with Global Fund funding, however,
fail to support this concern. Another concern is that
the observed declines in adult mortality may simply re-
flect the dynamic ebb of the HIV epidemic that would
have occurred also without Global Fund funding. While
this is not a hypothesis that our analysis can fully ex-
clude, this is less likely to explain our findings given the
Global Fund’s large infusion of financial resources to
ART programs, the high efficacy of ART in reducing
mortality among HIV+ individuals, the dose–response
relationship that we find, whereby greater Global Fund
disbursements led to greater subsequent declines in
mortality, and the dramatic reversal of adult mortality
trends after the introduction of ART documented in
other contexts [34, 35]. Strong causal inference is chal-
lenging in the absence of ex ante evaluation design or
natural experiments, and our aim is to make a careful
and measured attempt to estimate the Global Fund’s
impacts despite the challenging causal landscape.
While we accounted for possible interactions between
the Global Fund and PEPFAR, as well as controlled for
health aid besides the Global Fund, we did not assess
interactions between Global Fund and other major multi-
country donors such as the US President’s Malaria Initia-
tive [36]. Our study does not preclude additional important
survival benefits from of concurrent economic develop-
ment, health system improvement, and technological
advancements; nevertheless, the multivariate panel re-
gressions suggest that the Global Fund had an effect on
accelerating adult mortality reductions. The observa-
tional approaches we used in this analysis demonstrate
important associations of the Global Fund with mortal-
ity changes, but cannot prove a causal link. Rather, we
show that the epidemiological evidence is consistent
with three narratives: that the Global Fund played a
role in the reduction of adult mortality, that it played a
role in reducing malaria burden among children, and
that it did not measurably contribute to all-cause mor-
tality reductions among under-5 children. We do not
claim to prove these narratives, but rather raise the
burden of proof for any claims to the contrary. The
study provides a first-order estimate of the Global
Fund’s relationship with mortality changes, though the
Yan et al. BMC Public Health  (2015) 15:977 Page 8 of 10
effects may be variable in smaller country subsets or in-
dividual countries.
Conclusion
Global Fund support was significantly associated with ac-
celerated reductions in adult mortality and malaria-
specific under-five mortality, across all recipient countries
and within the subsample of Sub-Saharan countries, and
independent from effects of PEPFAR’s concurrent funding.
However, we observe no significant association between
Global Fund support and relative changes in all-cause
under-five mortality. These findings are consistent with an
important positive health impact achieved so far, as well
as ongoing new opportunities for this global health initia-
tive to further enhance its impact.
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